NCT00564057

Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine

Effects of Antihypertensive Treatment on Cardiac Remodelling and Metabolic Profile in HIV Infected Patients: Randomized Longitudinal Study With Candesartan Versus Lercanidipine

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Università degli Studi dell'Insubria · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Human immunodeficiency virus infection and highly active antiretroviral therapy (HAART) are associated with an increased risk of cardiovascular disease: a wide range of alterations in lipid and glucose metabolism has been increasingly recognized in HIV patients treated with HAART. Few data are available on the effects of antihypertensive treatment on cardiac morpho-functional characteristics and metabolic parameters in HIV patients. Aim of the study is to assess the effects of chronic therapy with angiotensin receptor blocker(candesartan)or calcium channel blocker (lercanidipine)on metabolic profile and cardiac remodelling in HIV hypertensive patients.

Conditions

• HIV Infections
• Hypertension

Interventions

Type	Name	Description
DRUG	candesartan	tablet 8-16 mg once daily, one year
DRUG	lercanidipine	tablets 10-20 mg once daily, one year

Timeline

• Start date: 2007-09-01
• Completion: 2009-09-01
• First posted: 2007-11-27
• Last updated: 2007-12-06

Locations

1 site across 1 country: Italy